EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, EyePoint Pharmaceuticals's enterprise value is $437.36 Mil.
EyePoint Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $56.04 Mil. Therefore, EyePoint Pharmaceuticals's EV-to-Revenue for today is 7.80.
The historical rank and industry rank for EyePoint Pharmaceuticals's EV-to-Revenue or its related term are showing as below:
EYPT'
s EV-to-Revenue Range Over the Past 10 Years
Min: -0.44 Med: 6.41 Max: 70.22
Current: 7.8
During the past 13 years, the highest EV-to-Revenue of EyePoint Pharmaceuticals was 70.22. The lowest was -0.44. And the median was 6.41.
EYPT's EV-to-Revenue is ranked better than 57.09% of 995
companies
in the Biotechnology industry
Industry Median: 7.63
vs EYPT: 7.80
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of EyePoint Pharmaceuticals's EV-to-Revenue
For the Biotechnology subindustry, EyePoint Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EyePoint Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, EyePoint Pharmaceuticals's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where EyePoint Pharmaceuticals's EV-to-Revenue falls into.
EyePoint Pharmaceuticals's current Enterprise Value is $437.36 Mil.
EyePoint Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $56.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EyePoint Pharmaceuticals's share price for today is $10.18.
EyePoint Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.90.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EyePoint Pharmaceuticals EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EYPT has been successfully added to your 